Skip to main content
Top
Published in: Annals of Hematology 2/2006

01-02-2006 | Original Article

Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis

Authors: He Qi, Li Xiao, Wu Lingyun, Tao Ying, Liu Yi-Zhi, Ying Shao-Xu, Pu Quan

Published in: Annals of Hematology | Issue 2/2006

Login to get access

Abstract

To verify the expression of type 1 insulin-like growth factor receptor (IGF-IR) and its impact on hematopoietic cells apoptosis in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), marrow samples from 16 patients with MDS and 16 patients with AML were examined along with 16 healthy donors as controls. Immunocytochemical methods (alkaline phosphatase anti-alkaline phosphatase) and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (fluorescence) were used simultaneously on nucleated cell cytospins. The ratio of IGF-IR positive cells and apoptotic cells as well as the relationship between them were then analyzed separately. A quantitative real-time reverse transcriptase–polymerase chain reaction (PCR) was administrated for six MDS cases and two normal controls to validate IGF-IR expression detected by immunochemistry. In our assay, IGF-IR appeared to have higher to lower expression rate in turn from AML (86.8±13.8%) to MDS (56.8±14.3%) and then to normal controls (40.4±9.6%) (P<0.01 between each group). In MDS nucleated cells, IGF-IR showed stronger expression in refractory anemia with excess blasts (RAEB)/RAEB in transformation/chronic myelomonocytic leukemia subgroup when compared to RA/RA with ringed sideroblasts cases (64.1±3.2 vs 53.5±16.2%) (P>0.05). Nucleated cells from MDS marrow underwent more apoptosis (5.4±3.0%) than that in normal marrow (1.2±0.9%) (P<0.01) and AML marrow (0.3±0.4%) (also, P<0.01 between each compared group). For both AML and MDS cases, apoptotic signals presented mainly in individual IGF-IR negative cells (9.0±4.8%) and less so in IGF-IR positive cells (1.4±2.4%) (P<0.01). When analyzed by groups, cell number with IGF-IR expression showed a negative correlation to apoptotic cells amount (r=−0.852; P<0.01) but positive correlation to their blast count (r=0.677; P<0.01). Outcome from real-time quantitative PCR appeared to have a trend of enhanced IGF-IR expression in advanced MDS subtypes. In conclusion, overexpression of IGF-IR existed in hematopoietic cells in MDS and AML marrows, which appeared to be contributed to disease progress.
Literature
1.
go back to reference Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19:5574–5581CrossRefPubMed Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19:5574–5581CrossRefPubMed
2.
go back to reference Wu Y, Tewari M, Cui S et al (1996) Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J Cell Physiol 168:499–509CrossRefPubMed Wu Y, Tewari M, Cui S et al (1996) Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J Cell Physiol 168:499–509CrossRefPubMed
3.
go back to reference Coppola D, Saunders B, Fu L et al (1999) The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 59:3264–3270PubMed Coppola D, Saunders B, Fu L et al (1999) The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 59:3264–3270PubMed
4.
go back to reference Poulaki V, Mitsiades CS, Kotoula V et al (2002) Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 161:643–654PubMed Poulaki V, Mitsiades CS, Kotoula V et al (2002) Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 161:643–654PubMed
5.
go back to reference Yee D, Rosen N, Favone RE et al (1991) The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer Treat Res 53:93–106PubMed Yee D, Rosen N, Favone RE et al (1991) The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer Treat Res 53:93–106PubMed
6.
go back to reference Singleton JR, Randolph AE, Feldman EL (1996) Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 56:4522–4529PubMed Singleton JR, Randolph AE, Feldman EL (1996) Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 56:4522–4529PubMed
7.
go back to reference Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22:6589–6597CrossRefPubMed Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22:6589–6597CrossRefPubMed
8.
go back to reference Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113(2):316–328CrossRefPubMed Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113(2):316–328CrossRefPubMed
9.
go back to reference Camirand A, Zakikhani M, Young F, Pollak M (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7(4):R570–R579CrossRefPubMed Camirand A, Zakikhani M, Young F, Pollak M (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7(4):R570–R579CrossRefPubMed
10.
go back to reference Raza A, Mundle S, Iftikhar A, et al (1995) Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143–154PubMedCrossRef Raza A, Mundle S, Iftikhar A, et al (1995) Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143–154PubMedCrossRef
11.
go back to reference Morrison TB, Weis JJ, Wittwer CT (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24(6):954–958, 960, 962PubMed Morrison TB, Weis JJ, Wittwer CT (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24(6):954–958, 960, 962PubMed
12.
go back to reference Shimon I, Shpilberg O (1995) The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 19:233–240CrossRefPubMed Shimon I, Shpilberg O (1995) The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 19:233–240CrossRefPubMed
13.
go back to reference Zumkeller W, Burdach S (1999) The insulin-like growth factor system in normal and malignant hematopoietic cells. Blood 94:3653–3657PubMed Zumkeller W, Burdach S (1999) The insulin-like growth factor system in normal and malignant hematopoietic cells. Blood 94:3653–3657PubMed
14.
go back to reference Baier TG, Ludwig WD, Schonberg D, Hartman KK (1992) Characterisation of insulin-like growth factor I receptors of human acute lymphoblastic leukaemia (ALL) cell lines and primary ALL cells. Eur J Cancer 28A(6–7):1105–1110CrossRefPubMed Baier TG, Ludwig WD, Schonberg D, Hartman KK (1992) Characterisation of insulin-like growth factor I receptors of human acute lymphoblastic leukaemia (ALL) cell lines and primary ALL cells. Eur J Cancer 28A(6–7):1105–1110CrossRefPubMed
15.
go back to reference Schillaci R, GaleanoA, Becu-Villalobos D, Spinelli O, Sapia S, Bezares RF (2005) Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. Br J Haematol 130(1):58–66CrossRefPubMed Schillaci R, GaleanoA, Becu-Villalobos D, Spinelli O, Sapia S, Bezares RF (2005) Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. Br J Haematol 130(1):58–66CrossRefPubMed
16.
go back to reference He Q, Li X, Tao Y, Liu YZ, Yang LP, Ying SX (2005) Expression of insulin-like growth factor receptor type I in marrow nucleated cells from hematologic malignancies and its anti-apoptotic effect. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13(3):483–487PubMed He Q, Li X, Tao Y, Liu YZ, Yang LP, Ying SX (2005) Expression of insulin-like growth factor receptor type I in marrow nucleated cells from hematologic malignancies and its anti-apoptotic effect. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13(3):483–487PubMed
17.
go back to reference Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker RH Jr, Dantzer R, Kelley KW (1997) Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 138(1):362–368CrossRefPubMed Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker RH Jr, Dantzer R, Kelley KW (1997) Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 138(1):362–368CrossRefPubMed
18.
go back to reference Kellerer M, Obermaier-Kusser B, Ermel B, Wallner U, Haring HU, Petrides PE (1990) An altered IGF-I receptor is present in human leukemic cells. J Biol Chem 265(16):9340–9345PubMed Kellerer M, Obermaier-Kusser B, Ermel B, Wallner U, Haring HU, Petrides PE (1990) An altered IGF-I receptor is present in human leukemic cells. J Biol Chem 265(16):9340–9345PubMed
19.
go back to reference Valverde AM, Mur C, Brownlee M, Bentio M (2004) Susceptibility to apoptosis in insulin-like factor-I receptor-deficient brown adipocytes. Mol Biol Cell 15(11):5101–5117CrossRefPubMed Valverde AM, Mur C, Brownlee M, Bentio M (2004) Susceptibility to apoptosis in insulin-like factor-I receptor-deficient brown adipocytes. Mol Biol Cell 15(11):5101–5117CrossRefPubMed
20.
go back to reference Jasty R, Van Golen C, Lin HJ, Solomon G, Heidelberger K, Polverini P, Opipari A, Feldman E, Castle VP (2001) Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia 3(4):304–313CrossRefPubMed Jasty R, Van Golen C, Lin HJ, Solomon G, Heidelberger K, Polverini P, Opipari A, Feldman E, Castle VP (2001) Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia 3(4):304–313CrossRefPubMed
21.
go back to reference Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27(1):27–35CrossRefPubMed Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27(1):27–35CrossRefPubMed
22.
go back to reference Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64(23):8620–8629CrossRefPubMed Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64(23):8620–8629CrossRefPubMed
Metadata
Title
Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis
Authors
He Qi
Li Xiao
Wu Lingyun
Tao Ying
Liu Yi-Zhi
Ying Shao-Xu
Pu Quan
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2006
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-005-0031-y

Other articles of this Issue 2/2006

Annals of Hematology 2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine